Quarterly report
Open the filing on sec.gov
Entrada Therapeutics, Inc. (TRDA)
Nasdaq: TRDA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2016
The companyfiscal 2025, as filed
Revenue$25.4M-87.9%
Net income-$144M-319.0%
Earnings per share$-3.47-306.5%
Operating cash flow-$129M-209.2%
Cash$94.3M-10.3%
Debtn/a
Shareholders’ equity$306M-28.6%
Shares, diluted41.4M+6.1%
Return on equity-47.0%
The recordfrom its filings
Filings in 202660
Newest filingNov 5 · 10-Q
Annual reportFeb 26, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$5.4M
Insider buys, 12 months$0.00
Patents granted6
Filer categoryAccelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $4.0MNet income -$161MCash from operations -$136Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.